局部放疗联合CHOP方案化疗治疗中晚期非霍奇金淋巴瘤的效果及安全性

Efficacy and Safety of Local Radiotherapy Combined with CHOP Chemotherapy in the Treatment of Advanced Non-Hodgkin Lymphoma

目的:探讨局部放疗联合CHOP方案化疗治疗中晚期非霍奇金淋巴瘤(NHL)的效果及安全性。方法:招募2012年2月-2013年2月笔者所在医院住院治疗的90例中晚期NHL患者为研究对象。采用随机分组信件法将受试者分为观察组和对照组,每组45例。对照组采用CHOP方案化疗,观察组在CHOP化疗后采用原始受累淋巴结区放疗。随访3年,比较两组1年生存率和3年生存率、不良反应(胃肠反应、白细胞降低、脱发及心电图)发生情况及治疗有效率。结果:观察组治疗有效率明显高于对照组,差异有统计学意义(P<0.05)。观察组1年生存率和3年生存率均明显高于对照组,差异均有统计学意义(P<0.05)。两组Ⅲ~Ⅳ级胃肠反应、白细胞降低、脱发及心电图改变发生率对比,差异均无统计学意义(P>0.05)。结论:局部放疗联合CHOP方案化疗可以提高中晚期NHL患者近远期疗效,安全性较高,值得临床推广。

Objective:To evaluate the efficacy and safety of local radiotherapy combined with CHOP chemotherapy in the treatment of advanced non- Hodgkin lymphoma(NHL).Method:From February 2012 to February 2013,a total of 90 patients with advanced NHL who were hospitalized in the author’s hospital were enrolled.Patients were divided into the observation group and the control group by randomized letter method,with 45 cases in each group.The control group received CHOP chemotherapy,and the observation group received radiotherapy in the original affected lymph node area after CHOP chemotherapy.After 3 years of follow-up,the 1-year survival rate and 3-year survival rate,the adverse reactions(gastrointestinal reaction,leukopenia,alopecia and electrocardiogram) and the treatment effectiveness were compared between the two groups.Result:The treatment efficiency of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).The 1-year survival rate and 3-year survival rate of the observation group were significantly higher than that of the control group,and the differences were statistically significant(P<0.05).The incidence of Ⅲ-Ⅳ gastrointestinal reaction, leukopenia,alopecia and electrocardiogram change were compared between the two groups,and the differences were not statistically significant(P>0.05). Conclusion:Local radiotherapy combined with CHOP chemotherapy can improve the short and long term efficacy of advanced NHL,and it is safe and worthy of clinical promotion.